These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30838003)

  • 1. Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT.
    Terrinoni M; Holmgren J; Lebens M; Larena M
    Front Immunol; 2019; 10():269. PubMed ID: 30838003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling.
    Larena M; Holmgren J; Lebens M; Terrinoni M; Lundgren A
    J Immunol; 2015 Apr; 194(8):3829-39. PubMed ID: 25786687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity.
    Terrinoni M; Holmgren J; Lebens M; Larena M
    Sci Rep; 2019 Feb; 9(1):2812. PubMed ID: 30808871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells.
    Veglia F; Sciaraffia E; Riccomi A; Pinto D; Negri DR; De Magistris MT; Vendetti S
    Infect Immun; 2011 Mar; 79(3):1300-10. PubMed ID: 21149590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.
    Lycke N; Holmgren J
    Immunology; 1986 Oct; 59(2):301-8. PubMed ID: 3021614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating dendritic cells to optimize mucosal immunization protocols.
    Williamson E; Westrich GM; Viney JL
    J Immunol; 1999 Oct; 163(7):3668-75. PubMed ID: 10490961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
    Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N
    Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal immunization in the ear with cholera toxin and its non-toxic β subunit promotes efficient Th1 and Th17 differentiation dependent on migrating DCs.
    Meza-Sánchez D; Pérez-Montesinos G; Sánchez-García J; Moreno J; Bonifaz LC
    Eur J Immunol; 2011 Oct; 41(10):2894-904. PubMed ID: 21792876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.
    Lebens M; Terrinoni M; Karlsson SL; Larena M; Gustafsson-Hedberg T; Källgård S; Nygren E; Holmgren J
    Vaccine; 2016 Apr; 34(18):2121-8. PubMed ID: 26973069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
    Zhang P; Lewis JP; Michalek SM; Katz J
    Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.
    Bagley KC; Abdelwahab SF; Tuskan RG; Fouts TR; Lewis GK
    Infect Immun; 2002 Oct; 70(10):5533-9. PubMed ID: 12228279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N
    Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct interaction between cholera toxin and dendritic cells is required for oral adjuvant activity.
    Gustafsson T; Hua YJ; Dahlgren MW; Livingston M; Johansson-Lindbom B; Yrlid U
    Eur J Immunol; 2013 Jul; 43(7):1779-88. PubMed ID: 23649516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency in Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin.
    Sun JB; Holmgren J; Larena M; Terrinoni M; Fang Y; Bresnick AR; Xiang Z
    Front Immunol; 2017; 8():1119. PubMed ID: 28951732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERdj5 in Innate Immune Cells Is a Crucial Factor for the Mucosal Adjuvanticity of Cholera Toxin.
    Kim MS; Yi EJ; Kim YI; Kim SH; Jung YS; Kim SR; Iwawaki T; Ko HJ; Chang SY
    Front Immunol; 2019; 10():1249. PubMed ID: 31275300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA.
    Wakabayashi A; Shimizu M; Shinya E; Takahashi H
    Cell Death Dis; 2018 May; 9(6):631. PubMed ID: 29795370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera toxin enhances interleukin-17A production in both CD4
    Tsai HC; Velichko S; Lee S; Wu R
    Immunology; 2018 Jul; 154(3):500-509. PubMed ID: 29377102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action.
    Grdic D; Smith R; Donachie A; Kjerrulf M; Hörnquist E; Mowat A; Lycke N
    Eur J Immunol; 1999 Jun; 29(6):1774-84. PubMed ID: 10382739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
    Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
    Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.